Price (delayed)
$1.38
Market cap
$9.65M
P/E Ratio
1.68
Dividend/share
N/A
EPS
$0.82
Enterprise value
$52.26M
Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.
There are no recent dividends present for NERV.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.